公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Modelling NAFLD disease burden in four Asian regions—2019-2030 | Estes C.; Chan H.L.Y.; Chien R.N.; Chuang W.-L.; Fung J.; Goh G.B.-B.; Hu T.H.; Huang J.-F.; Jang B.K.; Jun D.W.; JIA-HORNG KAO ; Lee J.-W.; Lin H.-C.; Razavi-Shearer K.; Seto W.-K.; Wong G.L.H.; Wong V.W.S.; Razavi H. | Alimentary Pharmacology and Therapeutics | 87 | 76 | |
2022 | Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data | Lim Y.-S.; Seto W.-K.; Kurosaki M.; Fung S.; JIA-HORNG KAO ; Hou J.; Gordon S.C.; Flaherty J.F.; Yee L.J.; Zhao Y.; Agarwal K.; Lampertico P. | Alimentary Pharmacology and Therapeutics | 12 | 11 | |
2011 | Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score | Yang H.-I.; Yuen M.-F.; Chan H.L.Y.; Han K.-H.; PEI-JER CHEN ; Kim D.-Y.; Ahn S.-H.; Chen C.-J.; Wong V.W.S.; Seto W.-K. | The Lancet Oncology | 502 | 479 |